An observational study in Acute Respiratory Distress Syndrome (ARDS) and Ventilator-induced Lung Injury, sponsored by XiaoJing Zou,MD. Recruiting at 4 sites in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-05-13.
Sponsored by XiaoJing Zou,MD · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 146 studies in Respiratory Distress Syndrome with a site in China — 54 open to participants now, 55 under way, 6 of them phase 3. Respiratory Distress Syndrome · China.
Among the 146 studies in Respiratory Distress Syndrome with a site in China, this one is the 14th largest by planned enrollment of the 65 observational ones that give a count, is one of 13 that started in 2025, is one of 65 observational ones, reaches primary completion later than 43 of the 54 other live ones, and was the 118th registered.
1,389 studies on the registry are indexed under Respiratory Distress Syndrome; 281 are open to participants now.
Browse Respiratory Distress Syndrome studies →54 of the 146 studies in Respiratory Distress Syndrome with a site in China are open now. Recruiting first, the newest first:
Southeast University, China · Sites in China
Ruijin Hospital · Sites in China
Ages 18+
Southeast University, China · Sites in China
Ages 18+
Southeast University, China · Sites in China
Ages 18+
Bin Du · Sites in China
Ages 18+
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 196 Respiratory Distress Syndrome studies recruiting now, 116 (59%) set no upper age limit and 50 (26%) stop at 75 or younger; 52 take children under 18; 9 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
146 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 16 · Phase 3 7 · Phase 4 5
First in 2006; this study’s year is marked. 13 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 625 is above the median of 100 across 476 observational studies indexed under Respiratory Distress Syndrome.
Median enrollment 100 across the 81 interventional studies, 139 across the 65 observational. Of the 52 that completed or were terminated, 3 (6%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 146 have an industry lead sponsor. The 10 most frequent:
XiaoJing Zou,MD is the lead sponsor of 4 studies on the registry; 2 are open to participants now.
XiaoJing Zou,MD has 3 studies filed under Respiratory Distress Syndrome — fewer than ten, so there is no comparison to draw.
17 of the studies in Respiratory Distress Syndrome with a site in China that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07342205Phase 3Shanghai University of Traditional Chinese MedicineA Study on the Treatment of Patients With Acute Lung Injury Caused by Sepsis Through Microbiota Transplantation | 2027-06 |
| NCT05624450Phase 3AstraZenecaEfficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen | 2027-11-04 |
| NCT07798154Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyEffect of Spontaneous Breathing in APRV Mode on Respiratory Physiology of ARDS Patients | 2026-11 |
| NCT07413094Shanghai Yidian Pharmaceutical Technology Development Co., Ltd.Efficacy and Safety of YD0743 Treatment for Sepsis-Associated ARDS | 2026-12 |
| NCT06430554Zhongda HospitalPersonalized Ventilation Based on Ventilation-perfusion Mismatch and Lung Recruitability | 2026-12-30 |
Add all 17 to your calendar (.ics) → With an account.
Among the 146 studies in Respiratory Distress Syndrome with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This multicenter, prospective, observational study aims to develop and validate an EIT-based prognostic model for ARDS. By focusing on the pathophysiological characteristics of ARDS and the causes of ventilator-induced lung injury, the investigators intend to establish a prognostic model that reveals lung injury and heterogeneity, enabling risk stratification and guiding individualized treatment.
This is a prospective, multicenter, observational cohort study that will enroll adult patients (aged 18-80 years) diagnosed with acute respiratory distress syndrome (ARDS) per the new 2023 ARDS global definition.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Training cohort
Other: Not applicable- observational study
Validation cohort
Other: Not applicable- observational study
Not applicable- observational study
28-day mortality rate
Time frame: From date of study enrollment (Day 0) until Day 28
ICU mortality rate
Time frame: From ICU admission to discharge, up to 24 weeks
60-day all-cause mortality rate
Time frame: 60 days post-enrollment
90-day all-cause mortality rate
Time frame: 90 days post-enrollment
Duration of mechanical ventilation (days)
Time frame: From intubation to successful extubation, up to 28 days
Ventilator-free days (VFDs) at 28 days
Time frame: 28 days post-enrollment
ICU length of stay (days)
Time frame: From ICU admission to discharge, up to 24 weeks
Hospital length of stay
Time frame: From hospital admission to discharge, up to 24 weeks
Plan to share: Yes
No publications or documents are linked to this record.
Started Apr 2025 (actual). Primary completion is estimated for Dec 2027, 32 months after the start.
Of 228 non-industry observational studies under Respiratory Distress Syndrome, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 47. This study's planned 32 months is above that.
Counting every sponsor, half of 234 studies reached it within 24 months; a quarter within 12 and three quarters within 49.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Respiratory Distress Syndrome →
XiaoJing Zou,MD